Home › Oropharyngeal Cancer › Virginia › Richmond
Oropharyngeal Cancer clinical trials in Richmond, VA
4 studies for Oropharyngeal Cancer are looking for participants at sites in and around Richmond (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
RecruitingPhase 1
- VCU Massey Comprehensive Cancer Center, Richmond
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Enhancing Oral Cancer Awareness
RecruitingHealthy volunteers welcome
- Virginia Commonwealth University, Richmond
Oropharyngeal Cancer trials in other cities
- Atlanta, GA8 studies
- Edison, NJ8 studies
- Chicago, IL7 studies
- New York City, NY6 studies
- Queens, NY5 studies
- St. Louis, MO5 studies
- Kansas City, MO5 studies
- Tampa, FL5 studies
- Los Angeles, CA5 studies
- Philadelphia, PA5 studies
- Milwaukee, WI5 studies
- Omaha, NE5 studies
Other studies in Richmond
- Breast Cancer26 studies
- Non-Small Cell Lung Cancer25 studies
- Prostate Cancer19 studies
- Heart Failure16 studies
- Lung Cancer14 studies
- Cardiovascular Disease13 studies
- Colorectal Cancer13 studies
- Steatotic Liver Disease12 studies
- Acute Myeloid Leukemia12 studies
- Metastatic Cancer12 studies
- Head and Neck Squamous Cell Carcinoma12 studies
- Melanoma11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.